Boehringer Ingelheim GMBH became the first company to publicly disclose the start of a biosimilar interchangeability trial since the US FDA issued draft guidance on the subject, displaying a fair bit of confidence in a product the agency hasn't even approved yet.
BI said July 27 that the first patient has been enrolled in its VOLTAIRE-X trial, which is designed to determine whether its proposed biosimilar, BI 695501, is interchangeable with the US-licensed version of AbbVie Inc.'s Humira (adalimumab)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?